Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Paxil CR on the upswing

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

GlaxoSmithKline's Paxil CR has recaptured 41% of its previous new prescriptions since its late June relaunch, the firm says July 28. "We're up to 2.2% new Rx share," Pharmaceuticals President David Stout told investors during GSK's second quarter earnings call. Paxil CR Q2 sales dropped 75% to $42 mil. Part of GSK's relaunch efforts include a 30-day free trial program (1Pharmaceutical Approvals Monthly July 2005, In Brief)...

You may also be interested in...

Paxil CR resumes shipments

GlaxoSmithKline resumes shipments of Paxil CR, four months after manufacturing problems led to FDA's seizure of the product at distribution and production facilities. Sales reps will offer 30-day free trial vouchers to support reintroduction. Resupply of Avandamet, which also was seized by FDA, is projected to begin by mid-July...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts